- Home
- TNGX vs REFI Comparison
TNGX vs REFI Comparison
Compare TNGX & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- REFI
- Stock Information
- Founded
- TNGX 2014
- REFI 2021
- Country
- TNGX United States
- REFI United States
- Employees
- TNGX N/A
- REFI N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- TNGX Health Care
- REFI Real Estate
- Exchange
- TNGX Nasdaq
- REFI Nasdaq
- Market Cap
- TNGX 723.2M
- REFI 274.3M
- IPO Year
- TNGX N/A
- REFI 2021
- Fundamental
- Price
- TNGX $6.91
- REFI $13.56
- Analyst Decision
- TNGX Strong Buy
- REFI Strong Buy
- Analyst Count
- TNGX 6
- REFI 3
- Target Price
- TNGX $10.00
- REFI $20.00
- AVG Volume (30 Days)
- TNGX 1.5M
- REFI 130.8K
- Earning Date
- TNGX 11-05-2025
- REFI 11-06-2025
- Dividend Yield
- TNGX N/A
- REFI 15.44%
- EPS Growth
- TNGX N/A
- REFI N/A
- EPS
- TNGX N/A
- REFI 1.84
- Revenue
- TNGX $24,296,000.00
- REFI $56,608,781.00
- Revenue This Year
- TNGX $6.56
- REFI $9.93
- Revenue Next Year
- TNGX N/A
- REFI $4.99
- P/E Ratio
- TNGX N/A
- REFI $7.26
- Revenue Growth
- TNGX N/A
- REFI 2.58
- 52 Week Low
- TNGX $1.03
- REFI $12.76
- 52 Week High
- TNGX $10.81
- REFI $16.29
- Technical
- Relative Strength Index (RSI)
- TNGX 54.33
- REFI 44.27
- Support Level
- TNGX $6.38
- REFI $13.08
- Resistance Level
- TNGX $6.90
- REFI $14.57
- Average True Range (ATR)
- TNGX 0.41
- REFI 0.32
- MACD
- TNGX -0.03
- REFI -0.10
- Stochastic Oscillator
- TNGX 57.39
- REFI 31.88
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.